The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.
Aucune reactivité croisée
Souris
Réactivité croisée (Details)
Human
Purification
Purified by protein-A affinity chromatography.
Pureté
> 95 % (by SDS-PAGE)
niveau d'endotoxine
Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
Immunogène
Recombinant soluble fragment (aa 95-281) of human TRAIL.
TNFSF10
Reactivité: Humain
WB, ELISA, ICC, IF
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Functional application: The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. Flow cytometry: Recommended dilution: 1-10 μg/mL.
Restrictions
For Research Use only
Concentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4
Agent conservateur
Azide free
Stock
4 °C
Stockage commentaire
Store at 2-8°C. Do not freeze.
Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: "TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors." dans: Leukemia, Vol. 16, Issue 1, pp. 67-73, (2002) (PubMed).
Antigène
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
TNF superfamily member 10,Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).,TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A